Asynchronous DNA Replication of Biallelically Expressed Genes in Human Peripheral Blood Lymphocytes as a Prognostic Sign of Cancer

The aim of the study was to identify and quantify lymphocytes with asynchronous replication of the AURKA and TP53 genes in cancer patients versus controls and to assess the diagnostic capabilities of this approach.

Materials and Methods. The study was carried out with peripheral blood lymphocytes probed for the AURKA and TP53 genes using the interphase fluorescence in situ hybridization (FISH) method (Vysis, USA and Kreatech, The Netherlands). The control group included 70 people: clinically healthy donors and patients with non-oncological diseases such as gastritis, pancreatitis, chronic calculous cholecystitis, bronchial asthma, peptic ulcer disease, inguinal hernia, arthrosis, myoma, hepatitis, epilepsy, chronic prostatitis, chronic tonsillitis, and rectal adenoma. The group of cancer patients included 219 people with various oncological diseases: gastric cancer (n=68), colorectal cancer (n=30), chronic lymphocytic leukemia (n=52), Hodgkin lymphoma (n=33), and polyneoplasia (n=41).

Results. In the control group, the mean frequency of lymphocytes with asynchronous gene replication (AGR) was 22.0±3.4% for AURKA and 18.0±3.2% for TP53; in the group of cancer patients, that was 36.8±4.8 and 28.4±5.1%, respectively. The excessive presence of lymphocytes with the AGR in cancer patients was consistent and statistically significant (p<0.0001). For the AURKA gene, the AGR-based cancer detection showed a sensitivity of 98.6±0.7%, a specificity of 100%, and an accuracy of 98.3±0.8%, and for the TP53 gene — 78.6±3.1, 98.5±0.9, and 85.9±2.6%, respectively.

Conclusion. This pilot study on lymphocytes with AGR of AURKA and TP53 genes in cancer patients can serve a basis for creating a new molecular cytogenetic technology for detecting malignant neoplasms in humans.

1. Zlokachestvennye novoobrazovaniya v Rossii v 2018 godu (zabolevaemost’ i smertnost’) [Malignant neoplasms in Russia in 2018 (morbidity and mortality)]. Kaprin A.D., Starinskiy V.V., Petrova G.V. (editors). Moscow: MNIOI im. A. Gertsena — filial FGBU “NMITs radiologii” Minzdrava Rossii; 2019; 250 p.
2. Blumenfeld B., Ben-Zimra M., Simon I. Perturbations in the replication program contribute to genomic instability in cancer. Int J Mol Sci 2017; 18(6): 1138, https://doi.org/10.3390/ijms18061138.
3. Hiratani I., Gilbert D.M. Replication timing as an epigenetic mark. Epigenetics 2009; 4(2): 93–97, https://doi.org/10.4161/epi.4.2.7772.
4. Donley N., Thayer M.J. DNA replication timing, genome stability and cancer: late and/or delayed DNA replication timing is associated with increased genomic instability. Semin Cancer Biol 2013; 23(2): 80–89, https://doi.org/10.1016/j.semcancer.2013.01.001.
5. Ryba T., Battaglia D., Chang B.H., Shirley J.W., Buckley Q., Pope B.D., Devidas M., Druker B.J., Gilbert D.M. Abnormal developmental control of replication-timing domains in pediatric acute lymphoblastic leukemia. Genome Res 2012; 22(10): 1833–1844, https://doi.org/10.1101/gr.138511.112.
6. Tomasetti C., Li L., Vogelstein B. Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. Science 2017; 355(6331): 1330–1334, https://doi.org/10.1126/science.aaf9011.
7. Amiel A., Litmanovich T., Gaber E., Lishner M., Avivi L., Fejgin M.D. Asynchronous replication of p53 and 21q22 loci in chronic lymphocytic leukemia. Hum Genet 1997; 101(2): 219–222, https://doi.org/10.1007/s004390050619.
8. Dotan Z.A., Dotan A., Litmanovitch T., Ravia Y., Oniashvili N., Leibovitch I., Ramon J., Avivi L. Modification in the inherent mode of allelic replication in lymphocytes of patients suffering from renal cell carcinoma: a novel genetic alteration associated with malignancy. Genes Chromosomes Cancer 2000; 27(3): 270–277, https://doi.org/10.1002/(sici)1098-2264 (200003)27:3270::aid-gcc73.0.co;2-7.
9. Mikhailova G.F., Tsepenko V.V., Shkavrova T.G., Goloub E.V. Asynchronous replication in oncological patients. Uspehi molekularnoj onkologii 2018; 5(1): 26–34, https://doi.org/10.17650/2313-805x-2018-5-1-26-34.
10. Silwal-Pandit L., Langerød A., Børresen-Dale A.L. TP53 mutations in breast and ovarian cancer. Cold Spring Harb Perspect Med 2017; 7(1): a026252, https://doi.org/10.1101/cshperspect.a026252.
11. Aubrey B.J., Strasser A., Kelly G.L. Tumor-suppressor functions of the TP53 pathway. Cold Spring Harb Perspect Med 2016; 6(5): a026062, https://doi.org/10.1101/cshperspect.a026062.
12. Torén W., Ansari D., Andersson R. Immunohistochemical investigation of prognostic biomarkers in resected colorectal liver metastases: a systematic review and meta-analysis. Cancer Cell Int 2018; 18(1): 217, https://doi.org/10.1186/s12935-018-0715-8.
13. Damodaran A.P., Vaufrey L., Gavard O., Gavard O., Prigent C. Aurora A kinase is a priority pharmaceutical target for the treatment of cancers. Trends Pharmacol Sci 2017; 38(8): 687–700, https://doi.org/10.1016/j.tips.2017.05.003.
14. Seeling J.M., Farmer A.A., Mansfield A., Cho H., Choudhary M. Differential selective pressures experienced by the Aurora kinase gene family. Int J Mol Sci 2018; 19(1): 72, https://doi.org/10.3390/ijms19010072.
15. Zhan S.J., Liu B., Linghu H. Identifying genes as potential prognostic indicators in patients with serous ovarian cancer resistant to carboplatin using integrated bioinformatics analysis. Oncol Rep 2018; 39(6): 2653–2663, https://doi.org/10.3892/or.2018.6383.
16. Zhou L., Du Y., Kong L., Zhang X., Chen Q. Identification of molecular target genes and key pathways in hepatocellular carcinoma by bioinformatics analysis. Onco Targets Ther 2018; 11: 1861–1869, https://doi.org/10.2147/ott.s156737.
17. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011; 144(5): 646–674, https://doi.org/10.1016/j.cell.2011.02.013.
18. Klein K.N., Gilbert D.M. Epigenetic vs. sequence-dependent control of eukaryotic replication timing. In: The initiation of DNA replication in eukaryotes. Kaplan D.L. (editor). Springer International Publishing Switzerland; 2016; p. 39–63, https://doi.org/10.1007/978-3-319-24696-3_3.
19. Macheret M., Halazonetis T.D. DNA replication stress as a hallmark of cancer. Annu Rev Pathol 2015; 10: 425–448, https://doi.org/10.1146/annurev-pathol-012414-040424.
20. Nagler A., Cytron S., Mashevich M., Korenstein-Ilan A., Avivi L. The aberrant asynchronous replication — characterizing lymphocytes of cancer patients — is erased following stem cell transplantation. BMC Cancer 2010; 10: 230, https://doi.org/10.1186/1471-2407-10-230.
21. Grinberg-Rashi H., Cytron S., Gelman-Kohan Z., Litmanovitch T., Avivi L. Replication timing aberrations and aneuploidy in peripheral blood lymphocytes of breast cancer patients. Neoplasia 2010; 12(8): 668–674, https://doi.org/10.1593/neo.10568.
22. Korenstein-Ilan A., Amiel A., Lalezari S., Lishner M., Avivi L. Allele-specific replication associated with aneuploidy in blood cells of patients with hematologic malignancies. Cancer Genet Cytogenet 2002; 139(2): 97–103, https://doi.org/10.1016/s0165-4608(02)00610-6.
23. Amiel A., Kirgner I., Gaber E., Manor Y., Fejgin M., Lishner M. Replication pattern in cancer: asynchronous replication in multiple myeloma and in monoclonal gammopathy. Cancer Genet Cytogenet 1999; 108(1): 32–37, https://doi.org/10.1016/s0165-4608(98)00107-1.
24. Amiel A., Kitay-Cohen Y., Fejgin M.D., Lishner M. Replication status as a marker for predisposition for lymphoma in patients with chronic hepatitis C with and without cryoglobulinemia. Exp Hematol 2000; 28(2): 156–160, https://doi.org/10.1016/s0301-472x(99)00140-x.
25. Amiel A., Litmanovitch T., Lishner M., Mor A., Gaber E., Tangi I., Fejgin M., Avivi L. Temporal differences in replication timing of homologous loci in malignant cells derived from CML and lymphoma patients. Genes Chromosomes Cancer 1998; 22(3): 225–231, https://doi.org/10.1002/(sici)1098-2264 (199807)22:3225::aid-gcc83.0.co;2-y.
26. Cytron S., Stepnov E., Bounkin I., Mashevich M., Dotan A., Avivi L. Epigenetic analyses in blood cells of men suspected of prostate cancer predict the outcome of biopsy better than serum PSA levels. Clin Epigenetics 2011; 2(2): 383–388, https://doi.org/10.1007/s13148-011-0029-3.
27. Dotan Z.A., Dotan A., Ramon J., Avivi L. Altered mode of allelic replication accompanied by aneuploidy in peripheral blood lymphocytes of prostate cancer patients. Int J Cancer 2004; 111(1): 60–66, https://doi.org/10.1002/ijc.20237.
28. Mikhaylova G.F., Tsepenko V.V., Shkavrova T.G., Golub E.V., Kaprin A.D. Method for screening malignant neoplasms in humans. Patent RU 2665965C1. 2017.

Tsepenko V.V., Shkavrova T.G., Cherkesov V.N., Golub E.V., Mikhailova G.F. Asynchronous DNA Replication of Biallelically Expressed Genes in Human Peripheral Blood Lymphocytes as a Prognostic Sign of Cancer. Sovremennye tehnologii v medicine 2021; 13(3): 33, https://doi.org/10.17691/stm2021.13.3.04